Innovative tests of plasmatic hemostasis

Laboratory Medicine

Volumn 39, Issue 4, 2008, Pages 225-230

  Stief, Thomas W ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 62749102823     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/DU1KKJ21VDAP37QN     Document Type: Review

References (65)

1. Fareed J, Hoppensteadt DA, Leya F, et al. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem. 1998;44:1845-1853.
2. Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood. 1984;64:791-796.
3. Favaloro EJ. Standardization, regulation, quality assurance and emerging technologies in hemostasis: Issues, controversies, benefits, and limitations. Semin Thromb Hemost. 2007;33:290-297.
4. Stief TW. Specific determination of plasmatic thrombin activity. Clin Appl Thromb Hemost. 2006;12:324-329.
5. Stief TW, Ijagha O, Weiste B, et al. Analysis of hemostasis alterations in sepsis. Blood Coagul Fibrinolysis. 2007;18:179-186.
6. Svendsen L, Blomback B, Blomback M, et al. Substrates for determination of trypsin, thrombin and thrombin-like enzymes. Folia Haematol Int Mag Klin Morphol Blutforsch. 1972;98:446-454.
7. Blomback M, Blomback B, Olsson P, el al. The assay of antithrombin using a synthetic chromogenic substrate for thrombin. Thromb Res. 1974;5:621-632.
8. Gaffney PJ, Lord K, Brasher M, et al. Problems in the assay of thrombin using synthetic peptides as substrates. Thromb Res. 1977;10:549-556.
9. Suomela H, Blomback M, Blomback B. The activation of factor X evaluated by using synthetic substrates. Thromb Res. 1977;10:267-281.
10. Aiyappa PA. Chromogenic substrate spectrophotometric assays for the measurement of clotting function. Ann N Y Acad Sci. 1981; 370:812-821.
11. Claeson G, Aurell L. Small synthetic peptides with affinity for proteases in coagulation and fibrinolysis: An overview. Ann N Y Acad Sci. 1981;370:798-811.
12. Triplett DA. New methods in coagulation. Crit Rev Clin Lab Sci. 1981;15:25-84.
13. Messmore HL Jr, Fareed J, Kniffin J, et al. Synthetic substrate assays of the coagulation enzymes and their inhibitors. Comparison with clotting and immunologic methods for clinical and experimental usage. Ann N Y Acad Sci. 1981;370:785-797.
14. Fareed J, Messmore HL, Walenga JM, et al. Laboratory evaluation of antithrombin III: A critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemost. 1982; 8:288-301.
15. Fareed J, Messmore HL, Walenga JM, et al. Synthetic peptide substrates in hemostatic testing. Crit Rev Clin Lab Sci. 1983;19:71-134.
16. Friberger P. Synthetic peptide substrate assays in coagulation and fibrinolysis and their application on automates. Semin Thromb Hemost. 1983;9:281-300.
17. Musgrave KA, Triplett DA. The use of synthetic substrates in the coagulation laboratory. Clin Lab Med. 1984;4:381-394.
18. Hutton RA. Chromogenic substrates in haemostasis. Blood Rev. 1987;1:201-206.
19. Gallimore MJ, Friberger P. Chromogenic peptide substrate assays and their clinical applications. Blood Rev. 1991;5:117-127.
20. Hemker HC, Al Dieri R, De Smedt E, et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553-561.
21. Stief TW, Weippert M, Kretschmer V, et al. Arginine inhibits hemostasis activation. Thromb Res. 2001;104:265-274.
22. Stief TW. Arginine inhibits serpins. Clin Appl Thromb Hemost. 2007;13:213-218.
23. Stief TW, Wieczerzak A, Renz H. Influence of coagulation factors on extrinsic thrombin generation. Blood Coagul Fibrinolysis. 2007;18:105-112.
24. Stief TW, Otto S, Renz H. The intrinsic coagulation activity assay. Blood Coagul Fibrinolysis. 2006;17:369-378.
25. Stief TW. Thrombin generation by exposure of blood to endotoxin: A simple model to study disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2006;12:137-161.
26. Stief TW. Thrombin generation by hemolysis. Blood Coagul Fibrinolysis. 2007;18:61-66.
27. Stief TW. Quantification of thrombin generation by trypsin. Medical and Biological Sciences (Scientific Journals International). 2007;1/ 2:1-8.
28. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894-1904.
29. Stief TW. The efficiency of anti-activated factor X and anti-activated factor II anticoagulants. Blood Coagul Fibrinolysis. 2007;18:265-269.
30. Stief TW. Inhibition of extrinsic hemostasis activation by low-molecular-weight heparin. Blood Coagul Fibrinolysis. 2006;17:633-637.
31. Stief TW, Otto S, Renz H. Influence of coagulation factors on intrinsic thrombin generation. Blood Coagul Fibrinolysis. 2007;18:67-71.
32. Stief TW. Inhibition of intrinsic thrombin generation. Drug Target Insights. 2006;2:6-11.
33. Stief TW, Richter A, Bünder R, et al. Monitoring of plasmin and plasminogen activator activity in blood of patients under fibrinolytic treatment by reteplase. Clin Appl Thromb Hemost. 2006;12:213-218.
34. 2x test - the corrected chi-square comparison against the control-mean. Clin Appl Thromb Hemost. 2007;13:73-100.
35. Stief TW, Fröhlich S, Renz H. Determination of the global fibrinolytic state. Blood Coagul Fibrinolysis. 2007;18:479-487.
36. Collen D, Lijnen HR. The fibrinolytic system in man. Crit Rev Oncol Hematol. 1986;4:249-301.
37. Horne MK 3rd, Goad JL, Merryman PK, et al. Comparison of the effect of histidine-rich glycoprotein and 6-aminohexanoic acid on plasmin production and fibrinolysis in vitro. Thromb Res. 2000;99:179-186.
38. Tsuchida-Straeten N, Ensslen S, Schafer C, et al. Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost. 2005;3:865-872.
39. Stief TW, Hinz F, Kurz J, Doss MO, Kretschmer V. A simple screening assay for certain fibrinolysis parameters (FIPA). Thromb Res. 2000;97:231-237.
40. Riddel JP Jr, Aouizerat BE, Miaskowski C, et al. Theories of blood coagulation. J Pediatr Oncol Nurs. 2007;24:123-131.
41. Nossent AY, Eikenboom JC, Bertina RM. Plasma coagulation factor levels in venous thrombosis. Semin Hematol. 2007;44:77-84.
42. Narayanan S, Hamasaki N. Current concepts of coagulation and fibrinolysis. Adv Clin Chem. 1998;33:133-168.
43. Adams GL, Manson RJ, Turner I, et al. The balance of thrombosis and hemorrhage in surgery. Hematol Oncol Clin North Am. 2007;21:13-24.
44. Hoffman M, Monroe DM. Coagulation 2006: A modern view of hemostasis. Hematol Oncol Clin North Am. 2007;21:1-11.
45. Mackie IJ, Bull HA. Normal haemostasis and its regulation. Blood Rev. 1989;3:237-250.
46. Ickx BE. New anticoagulant drugs: Monitoring and perioperative strategies. Acta Anaesthesiol Belg. 2006;57:409-418.
47. Fareed J, Hoppensteadt DA, Bick RL. Management of thrombotic and cardiovascular disorders in the new millenium. Clin Appl Thromb Hemost. 2003;9:101-108.
48. Agnelli G, Becattini C. New anticoagulants. Semin Thromb Hemost. 2006;32:793-802.
49. Edmunds LH Jr, Colman RW. Thrombin during cardiopulmonary bypass. Ann Thorac Surg. 2006;82:2315-2322.
50. Merriman L, Greaves M. Testing for thrombophilia: An evidence-based approach. Postgrad Med J. 2006;82:699-704.
51. Ofosu FA. Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. Thromb Haemost. 2006;96:568-577.
52. Tormene D, Gavasso S, Rossetto V, et al. Thrombosis and thrombophilia in children: A systematic review. Semin Thromb Hemost. 2006;32:724-728.
53. Arnout J, Hoylaerts MF, Lijnen HR. Haemostasis. Handb Exp Pharmacol. 2006;(176 Pt 2):1-41.
54. Pries AR, Kuebler WM. Normal endothelium. Handb Exp Pharmacol. 2006; (176 Pt 1):1-40.
55. Choi BG, Vilahur G, Ibanez B, et al. Measures of thrombosis and fibrinolysis. Clin Lab Med. 2006;26:655-678.
56. Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care. 2006;10:222.
57. Matijevic N, Wu KK. Hypercoagulable states and strokes. Curr Atheroscler Rep. 2006;8:324-329.
58. Machado FR, Silva E. Coagulation and sepsis. Endocr Metab Immune Disord Drug Targets. 2006;6:175-182.
59. Lasne D, Jude B, Susen S. From normal to pathological hemostasis. Can J Anaesth. 2006;53:S2-S11.
60. van der Putten RF, Glatz JF, Hermens WT. Plasma markers of activated hemostasis in the early diagnosis of acute coronary syndromes. Clin Chem Acta. 2006;371:37-54.
61. Barrowcliffe TW, Cattaneo M, Podda GM, et al. New approaches for measuring coagulation. Haemophilia. 2006;12:76-81.
62. Stief TW. The recalcified coagulation activity. Clin Appl Thromb Hemost. 2007 Dec 26; [Epub ahead of print].
63. Stief TW. Inhibition of thrombin generation in recalcified plasma. Blood Coagul Fibrinolysis. 2007;18:751-760.
64. Stief TW. The fibrinogen functional turbidimetric assay. Clin Appl Thromb Hemost. 2008;14:84-96.
65. Stief TW. Antithrombin III determination in nearly undiluted plasma. Lab Med. 2008;39:46-48.